Industry View on the Relative Importance of Clonality of Biopharmaceutical-Producing Cell Lines
|
|
- Christian Rose
- 6 years ago
- Views:
Transcription
1 Industry View on the Relative Importance of Clonality of Biopharmaceutical-Producing Cell Lines Christopher Frye, Eli Lilly & Company, Indianapolis IN Rohini Deshpande, Amgen Inc, Thousand Oaks CA Scott Estes, Biogen Inc, Cambridge MA Kathy Francissen, Genentech Inc, South San Francisco CA John Joly, Genentech Inc, South San Francisco CA Anthony Lubiniecki, Janssen R&D LLC, Malvern PA Trent Munro, Amgen Inc, Thousand Oaks CA Reb Russell, Bristol Myers Squibb, Pennington NJ Tongtong Wang, Eli Lilly & Company, Indianapolis IN Karin Anderson, Pfizer Inc, Andover MA
2 Introduction What is clonality? Why are production cells cloned? Can clonality ever be achieved in an absolute sense? What are the major Health Authority regulatory requirements? What is the role of clonality in the evaluation of product quality?
3 What is Clonality? Dictionary Definitions ability to be cloned (Dorland, Miller-Keane) ability to form clones (Saunders Veterinary) state of proliferation determined by the cell(s) of origin (McGraw-Hill Concise) For our purposes, we suggest that none of these are suitable, and what we probably mean by clonality is the degree of certainty that a cell line represents the progeny of a cloned cell
4 Why Are Production Cells Cloned? Production cells are cloned in order to Identify cells with high production levels Identify cells which make product of appropriate quality and post-translational modifications Identify cells adapted to thrive under production conditions, e.g., Possess adequate growth rate Maintain high viability for extended time periods Limit the pre-existing genetic variation of the cell line reflecting prior random mutations to be represented in the production cell line
5 Limiting Pre-existing Random Variation PDL 1 PDL 2 PDL 3 PDL 4
6 Can Clonality Ever Be Achieved in an Absolute Sense? It is possible to subject a mixed cell population to a cloning procedure which has a high probability of generating multiple separate populations of cells, many of which will likely have descended from a single cell. These are typically termed clones. The level of proof for each clone having been derived from a single cell varies with the method & technology employed, and is a probabalistic estimate rather than an absolute fact.
7 Can Clonality Ever Be Achieved in an Absolute Sense? It is impossible to use cloning to create a culture in which all cells are genetically identical due to the inherent minimum mutation rate of DNA replication, even under ideal circumstances unlikely to exist in immortalized cell lines. By the time that enough cells could be grown from a single cell to create a new cloned culture, further random DNA mutation will have occurred after cloning to ensure that some of the progeny cells are not identical to the single parental cell. This is an inherent property of DNA replication in all known life forms. Selective pressure agents & use of immortalized cell lines may further increase the rate of further random DNA mutation after cloning has occurred.
8 Can Clonality Ever Be Achieved in an Absolute Sense? So it is possible to achieve the act of cloning, and to be reasonably (but not totally) sure that the resulting culture is derived from a single cell, but it is not possible to assume or conclude that all cells in the resulting culture are genetically identical.
9 What Are the Regulatory Requirements of Major Health Authorities Regarding Clonality? FDA EMA ICH Other
10 What Is the Role of Clonality in the Evaluation of Product Quality? Assuring product quality depends on developing an integrated control strategy based on a multifaceted evaluation of: Cell line history Genetic manipulations introduced into the cell line Process of cell identification and cell cloning Process & analytical development Process validation and analytical validation Raw material controls Product testing and characterization Comparability assessment when appropriate Evaluation of DS & DP stability Characterization of degradants Adequate understanding of mechanism of action
11 What Is the Role of Clonality in the Evaluation of Product Quality? Recognizing the intent of the regulatory guidelines and the value of a cloning step, nevertheless, it should be reiterated that incorporation of a cloning step cannot prevent genetic and phenotypic heterogeneity within the population of cells that arise post-cloning as these events are inherent to the use of immortalized mammalian cell lines. Thus, assurance of product quality and consistency must rely on the other tools described above.
12 Conclusions Clonality is an essential but inherently limited feature of any integrated control strategy for a modern biopharmaceutical product, and should be evaluated appropriately in order to provide adequate assurance of product quality, along with all of the other components of the control strategy. Collectively, these integrated control principles have worked well to provide a steady stream of over 100 therapeutic biopharmaceuticals which have significantly benefited public health, while building an admirable record from the standpoint of product consistency and safety over the past 30+ years. A version of this talk has been submitted for publication in the IABS journal Biologicals
Welcome to the CMC Strategy Forum
Welcome to the CMC Strategy Forum We are pleased to welcome you to the CMC Strategy Forum. The purpose of the CMC Strategy Forum is to provide a venue for biotechnology/biological product discussion. The
More informationWelcome to the CMC Strategy Forum
Welcome to the CMC Strategy Forum We are pleased to welcome you to the CMC Strategy Forum. The purpose of the CMC Strategy Forum is to provide a venue for biotechnology/biological product discussion. The
More informationWelcome to. January 26, The Mayflower Hotel Washington, DC USA
Welcome to January 26, 2015 The Mayflower Hotel Washington, DC USA Mission Statement Provide a venue for biotechnology/biological product discussion that focuses on relevant CMC issues throughout the lifecycle
More informationGenetic Characterization of Production Cell Lines
Genetic Characterization of Production Cell Lines Luhong He and Christopher Frye 2017 CMC Strategy Forum Outlines Overview Genetic characterization strategy and case studies Transgene characterization
More informationWelcome to. January 27, Renaissance Mayflower Hotel Washington, DC USA
Welcome to January 27, 2014 Renaissance Mayflower Hotel Washington, DC USA What is CASSS? MISSION: What We Do CASSS is the global premier, non-profit scientific society facilitating the interaction among
More informationWelcome to the CMC Strategy Forum
Welcome to the CMC Strategy Forum We are pleased to welcome you to the CMC Strategy Forum. The purpose of the CMC Strategy Forum is to provide a venue for biotechnology/biological product discussion. The
More informationWelcome to the WCBP CMC Strategy Forum
Welcome to the WCBP CMC Strategy Forum We are pleased to welcome you to the 24 th WCBP CMC Strategy Forum. The purpose of the CMC Strategy Forum is to provide a venue for biotechnology/biological product
More informationA Roadmap to Biomanufacturing
MASSACHUSETTS INSTITUTE OF TECHNOLOGY A Roadmap to Biomanufacturing INTRODUCTION Join us in Principles of Biomanufacturing: Using Biotechnology to Manufacture Medicines and earn 3 CEUs and a MIT Professional
More informationBiotherapeutics Interest Group Workshop 64th ASMS Conference and Allied Topics, June 5 - June 9, 2016, San Antonio, TX
Biotherapeutics Interest Group Workshop 64th ASMS Conference and Allied Topics, June 5 - June 9, 2016, San Antonio, TX Damian Houde, Ph.D. and Ashley Ruth, Ph.D. The Biotherapeutics Interest Group (formerly
More informationWelcome to the CMC Strategy Forum Prior Knowledge: Learning from Our Successes and Failures to Improve Product Development and Manufacturing
Welcome to the CMC Strategy Forum Prior Knowledge: Learning from Our Successes and Failures to Improve Product Development and Manufacturing We are pleased to welcome you to the CMC Strategy Forum. The
More informationCMC Strategy Forum NA. Production Cell Line Development and Control of Product Consistency During Cell Cultivation Myths, Risks and Best Practices
CMC Strategy Forum NA Production Cell Line Development and Control of Product Consistency During Cell Cultivation Myths, Risks and Best Practices Welcome and Introductory Remarks Anthony Lubiniecki - CASSS
More informationWelcome to the CMC Strategy Forum
Welcome to the CMC Strategy Forum We are pleased to welcome you to the CMC Strategy Forum. The purpose of the CMC Strategy Forum is to provide a venue for biotechnology/biological product discussion. The
More information7 th International Symposium on Higher Order Structure of Protein Therapeutics (HOS 2018)
7 th International Symposium on Higher Order Structure of Protein Therapeutics (HOS 2018) Symposium Co-Chairs: Guodong Chen, Bristol-Myers Squibb Company David Keire, CDER, FDA April 9-11, 2018 Omni Providence
More informationWelcome to the CMC Strategy Forum
Welcome to the CMC Strategy Forum We are pleased to welcome you to the CMC Strategy Forum. The purpose of the CMC Strategy Forum is to provide a venue for biotechnology/biological product discussion. The
More informationPRELIMINARY PROGRAM Bay Area Discussion Group
PRELIMINARY PROGRAM Bay Area Discussion Group Co-chairs: Min Chen, Ultragenyx Pharmaceutical Vinaya Kapoor, Janssen, Pharmaceutical Companies of Johnson & Johnson South San Francisco Conference Center
More informationOpportunities for Accelerating Cell Line Development and Beyond
Opportunities for Accelerating Cell Line Development and Beyond European CM&C Strategy Forum May 24, 2017 Christopher Frye, Ph.D. Research Advisor & Group Leader Bioprocess R&D Presentation Outline CM&C
More informationParadigm Change in Manufacturing Operations
Technical Report No. 56 (Revised 2016) Application of Phase-Appropriate Quality System and cgmp to the Development of Therapeutic Protein Drug Substance (API or Biological Active Substance) Paradigm Change
More informationWelcome to the CMC Strategy Forum Phase-appropriate Method Validation Strategies: Policies and Practices to Support Clinical Development
Welcome to the CMC Strategy Forum Phase-appropriate Method Validation Strategies: Policies and Practices to Support Clinical Development We are pleased to welcome you to the CMC Strategy Forum. The purpose
More informationMontagna Symposium on the Biology of Skin
2014 Sustaining Members The Estée Lauder Companies, Inc. Galderma International Advancing Innovation in Dermatology, Inc. DUSA Pharmaceuticals, Inc. Johnson & Johnson Consumer & Personal Products Worldwide
More informationINVESTOR PRESENTATION 2018
INVESTOR PRESENTATION 2018 IMMUNOPRECISE ANTIBODIES, LTD. UNIT 3204-4464 MARKHAM STREET VICTORIA, BRITISH COLUMBIA V8Z 7X8, CANADA IMMUNOPRECISE.COM 1 Disclosures DISCLAIMER This presentation is not, and
More informationAn Industry Perspective: The Complexity of Postapproval CMC Changes and Proposed Regulatory Strategies. SPEAKER: Suzanne Murray Biogen
An Industry Perspective: The Complexity of Postapproval CMC Changes and Proposed Regulatory Strategies SPEAKER: Suzanne Murray Biogen Contents 1. BioPhorum Operations Group (BPOG) and the Post-approvals
More informationIndustry Biomanufacturing Capacity Overview Patti Seymour Senior Consultant BioProcess Technology Consultants, Inc. DCAT March 14 17, 2016
Global Biomanufacturing Trends, Capacity and Technology Drivers Industry Biomanufacturing Capacity Overview Patti Seymour Senior Consultant BioProcess Technology Consultants, Inc. DCAT March 14 17, 2016
More information8 th International Symposium on Higher Order Structure of Protein Therapeutics (HOS 2019)
8 th International Symposium on Higher Order Structure of Protein Therapeutics (HOS 2019) Symposium Co-Chairs: Katherine Bowers, FUJIFILM Diosynth Biotechnologies Guodong Chen, Bristol-Myers Squibb Company
More informationMontagna Symposium on the Biology of Skin
2016 Sustaining Members Anacor Pharmaceuticals, Inc. Galderma International Amgen USA Curtis T. Thompson, M.D. & LLC The David M.C. Ju Foundation Johnson & Johnson Consumer Inc. Tioga Pharmaceuticals,
More information4 th International Symposium on Higher Order Structure of Protein Therapeutics (HOS 2015)
4 th International Symposium on Higher Order Structure of Protein Therapeutics (HOS 2015) Symposium Co-chairs: Jamie Moore, Genentech, a Member of the Roche Group Linda Narhi, Amgen Inc. April 13-15, 2015
More informationMontagna Symposium on the Biology of Skin
2017 Sustaining Members Curtis T. Thompson, M.D. & LLC Novartis Pharmaceuticals Corporation Procter & Gamble Company Valeant Pharmaceuticals International, Inc. The Company of Biologists The David M.C.
More informationUSP Packing General Chapters <661.1>, <381>, <665>: An Industry Perspective on Elemental Impurities Compliance for Container/Closure
USP Packing General Chapters , , : An Industry Perspective on Elemental Impurities Compliance for Container/Closure Tim Shelbourn Co-chair, IQ Consortium ICH Q3D Compliance Working Group
More informationWelcome to the CMC Strategy Forum Europe 2017
Welcome to the CMC Strategy Forum Europe 2017 The 11 th annual CMC Strategy Forum Europe, organized by CASSS, will explore a number of critical topics focused on improving the quality in development and
More informationWelcome to the CMC Strategy Forum
Welcome to the CMC Strategy Forum We are pleased to welcome you to the CMC Strategy Forum. The purpose of the CMC Strategy Forum is to provide a venue for biotechnology/biological product discussion. The
More informationGLOBAL MARKETS FOR BIOENGINEERED PROTEIN DRUGS
GLOBAL MARKETS FOR BIOENGINEERED PROTEIN DRUGS BIO009G January 2017 Shalini Shahani Dewan Project Analyst ISBN: 1-62296-417-9 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationDemonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle
Process Performance Qualification Demonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle Wendy Zwolenski Lambert, CQM/OE, RAC CMC Strategy Forum January 28, 2013 aligns
More informationEuropean Medicines Agency Quality Working Party, London
Europe ggmbh Adalbertstraße 9 16548 Glienicke/Berlin Germany Tel: +49 (33056) 2377-10 Fax : +49 (33056) 2377-77 Georg Roessling, PhD General Manager Senior Vice President PDA Europe http://europe.pda.org
More informationWelcome to the CMC Strategy Forum
Welcome to the CMC Strategy Forum We are pleased to welcome you to the CMC Strategy Forum. The purpose of the CMC Strategy Forum is to provide a venue for biotechnology/biological product discussion. The
More informationTraditional Validation - Downstream
EMA Expert Workshop on Validation of Manufacturing for Biological Medicinal Products Tuesday 9 th April 2013 Traditional Validation - Downstream Norbert Hentschel Content of the Presentation 5. Should
More informationGlobal Industrial Perspective of Novel Biologicals Development
Global Industrial Perspective of Novel Biologicals Development Anthony S. Lubiniecki, Sc.D. Vice President, Technology Transfer & Project Planning Centocor R&D/Johnson & Johnson What Kind of Biotechnological
More informationInternational Association for Biologicals
International Association for Biologicals Presentation to Japanese Biologicals Forum by Tony Lubiniecki Tokyo, 16January2008 Scientific Society established in 1955 Headquartered in Switzerland Recognized
More informationAccelerated Path to Probe Biology through Deferred Cloning and Applying Platform Manufacturing Processes
Accelerated Path to Probe Biology through Deferred Cloning and Applying Platform Manufacturing Processes Rohini Deshpande, Ph.D., Executive Director Drug Substance Development, Amgen Thousand Oaks, CA
More informationPage2 Docket No. FDA-2013-N-0745 November 20, 2013
Via Electronic Submission Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Food and Drug Administration Safety and Innovation Act
More informationWelcome to the CMC Strategy Forum Europe 2016
Welcome to the CMC Strategy Forum Europe 2016 The 10 th annual CMC Strategy Forum Europe, organized by CASSS, will explore a number of critical topics focused on improving the quality in development and
More informationAPI Testing Requirements to Support the EI Risk Assessment. Elisabeth Corbett Associate Director, GRS-CMC, Bristol-Myers Squibb November 9, 2016
API Testing Requirements to Support the EI Risk Assessment Elisabeth Corbett Associate Director, GRS-CMC, Bristol-Myers Squibb November 9, 2016 Agenda Background Review of ICH Q3D Risk Assessment Principles
More informationGLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS
GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS BIO021E May 2016 Shalini Shahani Dewan Project Analyst ISBN: 1-62296-288-5 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA
More informationCC: Richard Levy, PDA; Denyse Baker, PDA
Bethesda Towers 4350 East West Highway Suite 150 Bethesda, MD 20814 USA Tel: +1 (301) 656-5900 Fax: +1 (301) 986-0296 www.pda.org OFFICERS Chair Harold Baseman ValSource Chair-Elect Martin VanTrieste Amgen
More informationBasis for Setting Acceptance Criteria. Basis for setting acceptance criteria
Basis for Setting Acceptance Criteria Representing EBE Brian Withers, Director CMC Regulatory Affairs, Abbott laboratories Basis for setting acceptance criteria Industry considerations: How to allow for
More informationStructures and functions of biomolecules & applications
Structures and functions of biomolecules & applications Purin Charoensuksai, PhD Department of Biopharmacy, Faculty of Pharmacy, Silpakorn University Definitions of Biological products http://www.fda.gov/aboutfda/transparency/basics/ucm194516.htm
More informationIntroduction to CMC Regulatory Affairs
Introduction to CMC Regulatory Affairs Bharathi Mamidipudi Regulatory Affairs Consultant II Syner-G Pharma Consulting, LLC Northeastern University, Boston November 10, 2016 My Background Experience ~4
More informationContinuous Biomanufacturing: Relevant Experiences with Development, Hybrid Implementation, and Emerging Opportunities
Continuous Biomanufacturing: Relevant Experiences with Development, Hybrid Implementation, and Emerging Opportunities Erik Fouts, Ph.D. VP and Site Head, Novato Operations 3-4 December ASTM E2968 14 Continuous
More informationPPQ-to-Approval Timelines Acceleration Approaches at BMS
PPQ-to-Approval Timelines Acceleration Approaches at BMS Marcus Boyer Bristol-Myers Squibb Associate Director Process Life-cycle Management Syracuse, NY USA Kristen Manchester Bristol-Myers Squibb Sr.
More informationVegetative and Cutting Propagation
15 Vegetative and Cutting Propagation Text Pages: 597 601; 623 628. Objectives: 1. Be able to describe and explain the origins of clones. 2. Be able to describe, explain, and summarize managing sources
More informationPrinciples of Genetics, Spring 2013, 4.0 credits
BIOL 362 Principles of Genetics, Spring 2013, 4.0 credits Date Lecture topic Chapter 23 Jan-Wed Introduction 1 28 Jan-Mon DNA: The genetic material 2 30 Jan-Wed DNA replication 3 04 Feb-Mon Gene function
More informationPPTA Regulatory Workshop June 13, 2016
PPTA Regulatory Workshop June 13, 2016 W. BRYAN SILVEY W. Bryan Silvey is the Senior Director, Global Regulatory Affairs/CMC for Baxalta US Inc. He is located at Baxalta s Westlake Village California regional
More informationfact sheet 3 Introduction to Biosimilars & Regulatory Requirements
3 fact sheet 3 Introduction to Biosimilars & Regulatory Requirements International Alliance of Patients Organizations CAN Mezzanine 49-51 East Road London N1 6AH United Kingdom International Federation
More informationMAS refers to the use of DNA markers that are tightly-linked to target loci as a substitute for or to assist phenotypic screening.
Marker assisted selection in rice Introduction The development of DNA (or molecular) markers has irreversibly changed the disciplines of plant genetics and plant breeding. While there are several applications
More informationWarm-Up. Describe how the Hershey-Chase experiment proved that DNA is the heritable molecule of genes.
Warm-Up Describe how the Hershey-Chase experiment proved that DNA is the heritable molecule of genes. Yesterday s Pictures 3D χ " = $ (o e)" e DNA protein protein protein protein protein Host Cell DNA
More informationEnabling Precision Medicine: The Role of Genetics in Clinical Drug Development A Workshop
A Collaboration between the Forum on Drug Discovery, Development, and Translation and the Roundtable on Genomics and Precision Health Enabling Precision Medicine: The Role of Genetics in Clinical Drug
More informationUse of DoE in Biopharmaceutical Industry. ProtAffin Biotechnologie AG
Use of DoE in Biopharmaceutical Industry ProtAffin Biotechnologie AG 3 d European DoE user Meeting, Lucerne, 1 st of June 2010 Alain Poncin (aponcin@protaffin.com) 2010 - : ProtAffin, Graz, Austria : Head
More informationImmunotoxicology Technical Committee (ITC) HESI Assembly of Members January 19, 2009
Immunotoxicology Technical Committee (ITC) HESI Assembly of Members January 19, 2009 Committee Leadership Dr. Ellen Evans (Schering-Plough Research Institute), Chair Dr. Tom Kawabata (Pfizer Inc.), Vice
More informationBio-Reagent Services. Custom Gene Services. Gateway to Smooth Molecular Biology! Your Innovation Partner in Drug Discovery!
Bio-Reagent Services Custom Gene Services Gateway to Smooth Molecular Biology! Gene Synthesis Mutagenesis Mutant Libraries Plasmid Preparation sirna and mirna Services Large-scale DNA Sequencing GenPool
More informationCourse Specification
The University of Southern Queensland Course Specification Description: Molecular Biology Subject Cat-Nbr Class Term Mode Units Campus BIO 3309 14362 2, 2002 ONC 1.00 TWMBA Academic Group: FOSCI Academic
More informationWelcome to the CMC Strategy Forum Europe 2015 Improving Biopharmaceutical Product Quality: Moving Implementation Forward
Welcome to the CMC Strategy Forum Europe 2015 Improving Biopharmaceutical Product Quality: Moving Implementation Forward The ninth annual CMC Strategy Forum Europe, organized by CASSS - An International
More informationI cover science and medicine, and believe this is biology's century.
1 of 6 4/19/2015 1:48 AM http://onforb.es/1bmd4q7 Matthew Herper Forbes Staff I cover science and medicine, and believe this is biology's century. PHARMA & HEALTHCARE 8/11/2013 @ 11:10AM 171,703 views
More information7 th International Symposium on Higher Order Structure of Protein Therapeutics (HOS 2018)
7 th International Symposium on Higher Order Structure of Protein Therapeutics (HOS 2018) Symposium Co-Chairs: Guodong Chen, Bristol-Myers Squibb Company David Keire, CDER, FDA April 9-11, 2018 Omni Providence
More informationWorkshop on Cytokine Release: State-of-the-Science, Current Challenges and Future Directions
Workshop on Cytokine Release: State-of-the-Science, Current Challenges and Future Directions Sponsored by the HESI Immunotoxicology Technical Committee Silver Spring, MD 22 October 2013 Objectives of the
More informationIntegrating HOS Techniques in CQA Assessment. Not all quality attributes are critical. Abbreviations
Integrating HS Techniques in CQA Assessment Tapan Das Biologics Development, Bristol-Myers Squibb April 5, 2017 6th International Symposium on Higher rder Structure of Protein Therapeutics. Gaithersburg
More informationPreview of New PDA Technical Report on Process Validation
PCMO (Paradigm Change to Manufacturing Operations) Process Validation and Verification: A Life- cycle Approach Preview of New PDA Technical Report on Process Validation Peter Levy PL Consulting, LLC peter@plevyconsulting.com
More information9 polymorphisms (SNPs) DNA fingerprinting with microsatellites, restriction
BIOL 260 Principles of Genetics, Fall 2013, 4.0 credits Date Lecture topic Chapter 06 Sep-Fri Introduction 1 DNA: The genetic material 2 DNA replication 3 Gene function 4 20 Sep-Fri: Last day for student-
More informationIndustry Proposal for Implementation of Single-Use User Requirements (SUUR) Toolkit. Joint BioPhorum / BPSA Team
Industry Proposal for Implementation of Single-Use User Requirements (SUUR) Toolkit Joint BioPhorum / BPSA Team Introduction Problem Statement implementation of single-use systems in GMP operations frequently
More informationWelcome to the CMC Strategy Forum Europe 2016
Welcome to the CMC Strategy Forum Europe 2016 The 10 th annual CMC Strategy Forum Europe, organized by CASSS, will explore a number of critical topics focused on improving the quality in development and
More informationCompeting for Image Leadership
Competing for Image Leadership By Peter Carlin, Ellen Gordon, Ruchika Kapur, and Shannon Clancy Image leadership in oncology is taking on increased importance as performance, customer satisfaction and
More informationAn Industry Perspective: Reducing the Complexity and Impact of Regulatory Changes in Latin America
An Industry Perspective: Reducing the Complexity and Impact of Regulatory Changes in Latin America SPEAKERS: Janett Mugaburu-Richards, M.S. Pfizer Inc. Kavita Ramalingam Iyer, Ph.D Merck & Co., Inc. Contents
More informationSequence Analysis Lab Protocol
Sequence Analysis Lab Protocol You will need this handout of instructions The sequence of your plasmid from the ABI The Accession number for Lambda DNA J02459 The Accession number for puc 18 is L09136
More informationName: Date: Living Environment Period:
Name: Living Environment Date: Period: Heredity & DNA 1. Arrange the following structures from largest to smallest. a chromosome a nucleus a gene 2. The diagram below represents a portion of a molecule
More informationAmes Data Submissions and Other Qualification Data for Impurities in Drug Substances
Ames Data Submissions and Other Qualification Data for Impurities in Drug Substances Mark W. Powley, Ph.D. Pharmacologist FDA/CDER/Office of New Drugs Outline Regulatory Background Ames Assay ICH M7 Submission
More informationTechnical Report No. 60 Process Validation: A Lifecycle Approach
Technical Report No. 60 Process Validation: A Lifecycle Approach Paradigm Change in Manufacturing Operations SM PDA Task Force on Technical Report No. 60: Process Validation: A Lifecycle Approach Authors
More informationCharacterization of Biotechnology Products: A Regulatory Perspective
Characterization of Biotechnology Products: A Regulatory Perspective Laurie Graham Acting Team Leader FDA/CDER/OPS/OBP Division of Monoclonal Antibodies WCBP 2013 1 Disclaimer The views and opinions expressed
More informationManufacturing Integrated Biologics Manufacturing
Manufacturing Integrated Biologics Manufacturing Integrated Biologics Manufacturing Abzena provides customer focused process development and manufacturing services for cgmp and non-gmp production of recombinant
More informationPharmacogenetics: A SNPshot of the Future. Ani Khondkaryan Genomics, Bioinformatics, and Medicine Spring 2001
Pharmacogenetics: A SNPshot of the Future Ani Khondkaryan Genomics, Bioinformatics, and Medicine Spring 2001 1 I. What is pharmacogenetics? It is the study of how genetic variation affects drug response
More informationBiology 105: Introduction to Genetics PRACTICE FINAL EXAM Part I: Definitions. Homology: Reverse transcriptase. Allostery: cdna library
Biology 105: Introduction to Genetics PRACTICE FINAL EXAM 2006 Part I: Definitions Homology: Reverse transcriptase Allostery: cdna library Transformation Part II Short Answer 1. Describe the reasons for
More informationMay 16-18, 2011 Beijing, China. Mark Rosolowsky, Ph.D. Vice President, Bristol-Myers Squibb
What You Should Know When You Make Manufacturing Changes to Biotechnology Products May 16-18, 2011 Beijing, China Mark Rosolowsky, Ph.D. Vice President, Global Regulatory Sciences-CMC Bristol-Myers Squibb
More informationBIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS
: TECHNOLOGIES AND GLOBAL MARKETS BIO061C April 2014 Jackson Highsmith Project Analyst ISBN: 1-56965-801-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free within
More informationWelcome to. April 4-5, DoubleTree by Hilton Hotel Silver Spring, MD USA
Welcome to April 4-5, 2016 DoubleTree by Hilton Hotel Silver Spring, MD USA What is CASSS? Practical Applications of Mass Spectrometry EUROPE JAPAN NORTH AMERICA SOUTH AMERICA CASSS is the leading non-profit
More informationNeutralising Assay Methodologies
Neutralising Assay Methodologies March 9 th, 2016 EMA workshop on immunogenicity assessment of biotechnology derived therapeutic proteins Shalini Gupta, PhD Amgen Inc. shalinig@amgen.com 1 Key Points About
More informationRegulatory Consideration for Biotechnology Products: Clonality of the Production Cell Bank
Regulatory Consideration for Biotechnology Products: Clonality of the Production Cell Bank Rashmi Rawat, Ph.D. Office of Biotechnology Products OPQ/CDER/FDA Informa Life Sciences Annual Cell Line Development
More informationCharacterization of a fusion protein under native and denaturing conditions with maxis II
Characterization of a fusion protein under native and denaturing conditions with maxis II Abstract The maxis II UHR-QTOF was used to characterize key attributes of a fusion protein in its native conformation
More informationPrecise Characterization of Intact Monoclonal Antibodies by the Agilent 6545XT AdvanceBio LC/Q-TOF
Precise Characterization of Intact Monoclonal Antibodies by the Agilent 6545XT AdvanceBio LC/Q-TOF Application Note Author David L. Wong Agilent Technologies, Inc. Santa Clara, CA, USA Introduction Monoclonal
More informationRBM Risk Based Monitoring GCP Training 12/SEP/2015. Gabor Kiss Synexus Hungary2015
RBM Risk Based Monitoring GCP Training 12/SEP/2015 Gabor Kiss Synexus Hungary2015 Agenda Why traditional monitoring must change? The landscape Regulatory Industry IT What can we expect? Transition period
More informationModeling the IT Value Paradox. Matt E. Thatcher and David E. Pingry
Modeling the IT Value Paradox Matt E. Thatcher and David E. Pingry Although profit-seeking firms continue to invest in information technology (IT), the results of the empirical search for IT value have
More informationIntroductions and Perspectives on International Harmonization
Introductions and Perspectives on International Harmonization FDA/PQRI Conference on Evolving Product Quality September 17 th 2014 Mark Rosolowsky, PhD Vice President Global Regulatory Sciences CMC Bristol-Myers
More informationDivision of Docket Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, rm Rockville, MD 20852
October 3, 2008 PDA Global Headquarters Bethesda Towers 4350 East West Highway Suite 200 Bethesda, MD 20814 USA Tel: +1 (301) 656-5900 Fax: +1 (301) 986-0296 www.pda.org OFFICERS Chair: John Shabushnig,
More informationBioSafe Introduction and rare disease activities
BioSafe Introduction and rare disease activities Tim MacLachlan, PhD, DABT Chair, BioSafe Leadership Committee Executive Director, Biologics Safety Assessment Preclinical Safety, Novartis BIOTECHNOLOGY
More informationTechnical Report No. 71 Emerging Methods for Virus Detection
Technical Report No. 71 Emerging Methods for Virus Detection PDA Emerging Methods for Virus Detection Technical Report Team Authors Arifa S. Khan, Ph.D., U.S. FDA/CBER, Co-Leader Kathryn E. King, Ph.D.,
More informationAPPLYING SCIENTIFIC CONSIDERATIONS AND STATISTICAL APPROACHES IN ANALYTICAL SIMILARITY ASSESSMENT
APPLYING SCIENTIFIC CONSIDERATIONS AND STATISTICAL APPROACHES IN ANALYTICAL SIMILARITY ASSESSMENT JENNIFER LIU CASSS CMC STRATEGY FORUM EUROPE 2017, MAY 22-24 BIOSIMILAR DEVELOPMENT BEGINS WITH THOROUGH
More informationWorld Health Organization. The Bioethics, Regulation, and Future of Genomic Modification. Aya Lahlou & Kenza El Bernoussi
World Health Organization The Bioethics, Regulation, and Future of Genomic Modification : Aya Lahlou & Kenza El Bernoussi Historical background This is a marvelous time for genetics, due largely to advances
More informationApplicazioni biotecnologiche
Applicazioni biotecnologiche Analisi forense Sintesi di proteine ricombinanti Restriction Fragment Length Polymorphism (RFLP) Polymorphism (more fully genetic polymorphism) refers to the simultaneous occurrence
More informationSEED CERTIFICATION AND PROGENY TESTING. Clayton E. Posey, Assistant Professor Department of Forestry Oklahoma State University, Stillwater, Okla.
SEED CERTIFICATION AND PROGENY TESTING Clayton E. Posey, Assistant Professor Department of Forestry Oklahoma State University, Stillwater, Okla. SEED CERTIFICATION According to the statements of the International
More informationCENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS
CENTRAL NERVOUS SYSTEM (CNS) : TECHNOLOGIES AND GLOBAL MARKETS BIO074C March 2016 Jackson Highsmith Project Analyst ISBN: 1-62296-246-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationAPS Science Curriculum Unit Planner
APS Science Curriculum Unit Planner Grade Level/Subject Biology DNA / DNA Technology Stage 1: Desired Results Enduring Understanding Advancements in our understanding of DNA have both solved and created
More informationDRAFT DOCUMENT FINAL COPY TO REFLECT CONFIRMED. Embed Innovations to Transform Your R&D Procurement Model and. Drive Scientific Activities Efficiency
Embed Innovations to Transform Your R&D Procurement Model and Drive Scientific Activities Efficiency April 30 May 1, 2018 Boston, US This conference exceeded all of my expectations. The topics, speakers
More informationGenetic analysis is extremely powerful, but also limited in the absence of other types of information
Genetic analysis is extremely powerful, but also limited in the absence of other types of information Mendel was interested in variation among peas as a formalism - because he realized that these phenotypes
More informationThe Advent of Subsequent Entry Biologics: Biosimilars Canada. The Advent of Subsequent Entry Biologics. Biosimilars in Canada
The Advent of Subsequent Entry Biologics: Biosimilars Canada The Advent of Subsequent Entry Biologics Biosimilars in Canada Spring 2014 Author: Patrick J. Mott, MSc. Editors Allison Hillier BA, MA Heather
More informationAn Overview of IQ s Position Paper: Early Development GMPs for Small-Molecule Specifications
An Overview of IQ s Position Paper: Early Development GMPs for Small-Molecule Specifications On behalf of Specifications Team Kirby Wong-Moon, Ph.D. Amgen Inc. Best Practices and Application of GMPs for
More information